FDA Approves Pfizer’s Adcetris for Relapsed or Refractory Large B-Cell Lymphoma

Posted on by admin

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ineligible for autologous stem cell transplantation.

Leave a Reply

Your email address will not be published. Required fields are marked *